Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199302 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01199302 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 67 participants.
The verdict
NCT01199302, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
Interventions
- BIOLOGICAL Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2011-02-02 |
| Est. Completion | 2011-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01199302
The ClinicalTrials.gov registry entry for NCT01199302 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brodalumab is the first listed.
NCT01199302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01199302 about?
NCT01199302 is a clinical study titled "Long-term Safety Study of Brodalumab in Adults With Crohn's Disease". The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
What is the current status of trial NCT01199302?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2011-02-02. Estimated completion is 2011-10-18.
What interventions are being tested in trial NCT01199302?
The interventions under investigation include: Brodalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01199302?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.